-------------------------------------------------------------------------------
      name:  <unnamed>
       log:  /workspace/logs/descriptive_tables.log
  log type:  text
 opened on:   6 Apr 2022, 14:51:36

. 
. **Set Ado file path
. adopath + "$projectdir/analysis/extra_ados"
  [1]  (BASE)      "/usr/local/stata/ado/base/"
  [2]  (SITE)      "/usr/local/ado/"
  [3]              "."
  [4]  (PERSONAL)  "~/ado/personal/"
  [5]  (PLUS)      "~/ado/plus/"
  [6]  (OLDPLACE)  "~/ado/"
  [7]              "/workspace/analysis/extra_ados"

. 
. **Use cleaned data from previous step
. use "$projectdir/output/data/file_eia_all.dta", clear

. 
. /*Tables=====================================================================
> ================*/
. *Baseline table by eia diagnosis
. preserve

. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent i
> qrmiddle(",")  ///
>         vars(age contn %3.0f \ ///
>                  agegroup cat %5.1f \ ///
>                  male bin %5.1f \ ///
>                  ethnicity cat %5.1f \ ///
>                  imd cat %5.1f \ ///
>                  bmicat cat %5.1f \ ///
>                  smoke cat %5.1f \ ///
>                  hypertension bin %5.1f \ ///
>                  diabetes bin %5.1f \ ///
>                  hba1ccatmm cat %5.1f \ ///
>                  chronic_cardiac_disease bin %5.1f \ /// 
>                  stroke bin %5.1f \ ///
>                  cancer bin %5.1f \ ///
>                  chronic_resp_disease bin  %5.1f \ ///
>                  chronic_liver_disease bin %5.1f \ ///
>                  ckd cat %5.1f \ ///
>                  egfr_cat_nomiss cat %5.1f \ ///
>                  esrf bin %5.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------+
  | factor                             N_T      N_1      N_2      N_3   m_T   m
> _1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------|
  | Age                             35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Age group                       35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Male                            35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Ethnicity                       35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Index of multiple deprivation   35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | BMI                             35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Smoking status                  35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Hypertension                    35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Diabetes                        35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | HbA1c                           35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic cardiac disease         35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Stroke                          35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Cancer                          35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic respiratory disease     35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic liver disease           35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic kidney disease          35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | eGFR                            35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | End-stage renal failure         35,388   11,888   11,661   11,839     0    
>  0     0     0 |
  +----------------------------------------------------------------------------
> ---------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> ---------------------------------+
  |                                 Total            RA               PsA      
>         AxSpA            p-value |
  |----------------------------------------------------------------------------
> ---------------------------------|
  |                                 N=35,388         N=11,888         N=11,661 
>         N=11,839                 |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Age                             49 (19)          49 (19)          49 (19)  
>         49 (19)           0.38   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Age group                                                                  
>                           0.83   |
  |    18-39                        13,132 (37.1%)   4,403 (37.0%)    4,369 (37
> .5%)    4,360 (36.8%)            |
  |    40-49                        5,623 (15.9%)    1,917 (16.1%)    1,830 (15
> .7%)    1,876 (15.8%)            |
  |    50-59                        5,962 (16.8%)    2,020 (17.0%)    1,936 (16
> .6%)    2,006 (16.9%)            |
  |    60-69                        4,728 (13.4%)    1,582 (13.3%)    1,558 (13
> .4%)    1,588 (13.4%)            |
  |    70-79                        3,729 (10.5%)    1,264 (10.6%)    1,218 (10
> .4%)    1,247 (10.5%)            |
  |    80+                          2,214 (6.3%)     702 (5.9%)       750 (6.4%
> )       762 (6.4%)               |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Male                            17,199 (48.6%)   5,752 (48.4%)    5,702 (48
> .9%)    5,745 (48.5%)     0.72   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Ethnicity                                                                  
>                           0.14   |
  |    White                        13,289 (37.6%)   4,486 (37.7%)    4,437 (38
> .0%)    4,366 (36.9%)            |
  |    Asian/Asian British          2,650 (7.5%)     836 (7.0%)       881 (7.6%
> )       933 (7.9%)               |
  |    Black                        2,639 (7.5%)     866 (7.3%)       867 (7.4%
> )       906 (7.7%)               |
  |    Mixed/Other                  7,977 (22.5%)    2,714 (22.8%)    2,601 (22
> .3%)    2,662 (22.5%)            |
  |                                 8,833 (25.0%)    2,986 (25.1%)    2,875 (24
> .7%)    2,972 (25.1%)            |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Index of multiple deprivation                                              
>                           0.47   |
  |    1 least deprived             24,806 (70.1%)   8,341 (70.2%)    8,213 (70
> .4%)    8,252 (69.7%)            |
  |    4                            7,012 (19.8%)    2,348 (19.8%)    2,258 (19
> .4%)    2,406 (20.3%)            |
  |    5 most deprived              3,570 (10.1%)    1,199 (10.1%)    1,190 (10
> .2%)    1,181 (10.0%)            |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | BMI                                                                        
>                           0.62   |
  |    Underweight (<18.5)          80 (0.2%)        32 (0.3%)        23 (0.2%)
>         25 (0.2%)                |
  |    Normal (18.5-24.9)           227 (0.6%)       71 (0.6%)        79 (0.7%)
>         77 (0.7%)                |
  |    Overweight (25-29.9)         275 (0.8%)       84 (0.7%)        108 (0.9%
> )       83 (0.7%)                |
  |    Obese I (30-34.9)            344 (1.0%)       115 (1.0%)       113 (1.0%
> )       116 (1.0%)               |
  |    Obese II (35-39.9)           357 (1.0%)       106 (0.9%)       140 (1.2%
> )       111 (0.9%)               |
  |    Obese III (40+)              590 (1.7%)       189 (1.6%)       204 (1.7%
> )       197 (1.7%)               |
  |                                 33,515 (94.7%)   11,291 (95.0%)   10,994 (9
> 4.3%)   11,230 (94.9%)           |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Smoking status                                                             
>                           0.99   |
  |    Never                        3,504 (9.9%)     1,183 (10.0%)    1,152 (9.
> 9%)     1,169 (9.9%)             |
  |    Former                       1,730 (4.9%)     582 (4.9%)       558 (4.8%
> )       590 (5.0%)               |
  |    Current                      10,589 (29.9%)   3,560 (29.9%)    3,468 (29
> .7%)    3,561 (30.1%)            |
  |                                 19,565 (55.3%)   6,563 (55.2%)    6,483 (55
> .6%)    6,519 (55.1%)            |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Hypertension                    7,144 (20.2%)    2,349 (19.8%)    2,374 (20
> .4%)    2,421 (20.4%)     0.36   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Diabetes                        7,094 (20.0%)    2,473 (20.8%)    2,328 (20
> .0%)    2,293 (19.4%)     0.021  |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | HbA1c                                                                      
>                           0.71   |
  |    HbA1c <58mmol/mol            1,575 (4.5%)     532 (4.5%)       534 (4.6%
> )       509 (4.3%)               |
  |    HbA1c >=58mmol/mol           271 (0.8%)       98 (0.8%)        91 (0.8%)
>         82 (0.7%)                |
  |                                 33,542 (94.8%)   11,258 (94.7%)   11,036 (9
> 4.6%)   11,248 (95.0%)           |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Chronic cardiac disease         7,141 (20.2%)    2,459 (20.7%)    2,226 (19
> .1%)    2,456 (20.7%)     0.002  |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Stroke                          7,079 (20.0%)    2,375 (20.0%)    2,370 (20
> .3%)    2,334 (19.7%)     0.50   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Cancer                          17,229 (48.7%)   5,849 (49.2%)    5,608 (48
> .1%)    5,772 (48.8%)     0.23   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Chronic respiratory disease     7,071 (20.0%)    2,387 (20.1%)    2,345 (20
> .1%)    2,339 (19.8%)     0.75   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Chronic liver disease           7,144 (20.2%)    2,467 (20.8%)    2,343 (20
> .1%)    2,334 (19.7%)     0.13   |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | Chronic kidney disease                                                     
>                           0.25   |
  |    No CKD                       15,817 (44.7%)   5,242 (44.1%)    5,233 (44
> .9%)    5,342 (45.1%)            |
  |    CKD                          19,571 (55.3%)   6,646 (55.9%)    6,428 (55
> .1%)    6,497 (54.9%)            |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | eGFR                                                                       
>                           0.31   |
  |    >=60/missing                 19,779 (55.9%)   6,573 (55.3%)    6,505 (55
> .8%)    6,701 (56.6%)            |
  |    30-59                        9,308 (26.3%)    3,156 (26.5%)    3,096 (26
> .6%)    3,056 (25.8%)            |
  |    <30                          6,301 (17.8%)    2,159 (18.2%)    2,060 (17
> .7%)    2,082 (17.6%)            |
  |----------------------------------------------------------------------------
> ---------------------------------|
  | End-stage renal failure         7,065 (20.0%)    2,366 (19.9%)    2,329 (20
> .0%)    2,370 (20.0%)     0.97   |
  +----------------------------------------------------------------------------
> ---------------------------------+
Data are presented as mean (SD) for continuous measures, and n (%) for categori
> cal measures.
 

. restore

. 
. *Baseline table by year of diagnosis
. preserve

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(age contn %3.0f \ ///
>                  agegroup cat %5.1f \ ///
>                  male bin %5.1f \ ///
>                  ethnicity cat %5.1f \ ///
>                  imd cat %5.1f \ ///
>                  bmicat cat %5.1f \ ///
>                  smoke cat %5.1f \ ///
>                  hypertension bin %5.1f \ ///
>                  diabetes bin %5.1f \ ///
>                  hba1ccatmm cat %5.1f \ ///
>                  chronic_cardiac_disease bin %5.1f \ /// 
>                  stroke bin %5.1f \ ///
>                  cancer bin %5.1f \ ///
>                  chronic_resp_disease bin  %5.1f \ ///
>                  chronic_liver_disease bin %5.1f \ ///
>                  ckd cat %5.1f \ ///
>                  egfr_cat_nomiss cat %5.1f \ ///
>                  esrf bin %5.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------+
  | factor                             N_T      N_1      N_2      N_3   m_T   m
> _1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------|
  | Age                             33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Age group                       33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Male                            33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Ethnicity                       33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Index of multiple deprivation   33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | BMI                             33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Smoking status                  33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Hypertension                    33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Diabetes                        33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | HbA1c                           33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic cardiac disease         33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Stroke                          33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Cancer                          33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic respiratory disease     33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic liver disease           33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | Chronic kidney disease          33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | eGFR                            33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  |----------------------------------------------------------------------------
> ---------------|
  | End-stage renal failure         33,769   11,362   11,213   11,194     0    
>  0     0     0 |
  +----------------------------------------------------------------------------
> ---------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> ------------------------------------------------------+
  |                                 Total            March 2019-March 2020   Ma
> rch 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  |                                 N=33,769         N=11,362                N=
> 11,213                N=11,194                        |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Age                             49 (19)          49 (19)                 49
>  (19)                 49 (19)                  0.97   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Age group                                                                  
>                                                0.78   |
  |    18-39                        12,543 (37.1%)   4,228 (37.2%)           4,
> 165 (37.1%)           4,150 (37.1%)                   |
  |    40-49                        5,366 (15.9%)    1,846 (16.2%)           1,
> 728 (15.4%)           1,792 (16.0%)                   |
  |    50-59                        5,669 (16.8%)    1,887 (16.6%)           1,
> 925 (17.2%)           1,857 (16.6%)                   |
  |    60-69                        4,515 (13.4%)    1,480 (13.0%)           1,
> 513 (13.5%)           1,522 (13.6%)                   |
  |    70-79                        3,548 (10.5%)    1,214 (10.7%)           1,
> 173 (10.5%)           1,161 (10.4%)                   |
  |    80+                          2,128 (6.3%)     707 (6.2%)              70
> 9 (6.3%)              712 (6.4%)                      |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Male                            16,421 (48.6%)   5,516 (48.5%)           5,
> 452 (48.6%)           5,453 (48.7%)            0.97   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Ethnicity                                                                  
>                                                0.13   |
  |    White                        12,629 (37.4%)   4,290 (37.8%)           4,
> 175 (37.2%)           4,164 (37.2%)                   |
  |    Asian/Asian British          2,529 (7.5%)     816 (7.2%)              87
> 4 (7.8%)              839 (7.5%)                      |
  |    Black                        2,516 (7.5%)     883 (7.8%)              77
> 7 (6.9%)              856 (7.6%)                      |
  |    Mixed/Other                  7,649 (22.7%)    2,562 (22.5%)           2,
> 505 (22.3%)           2,582 (23.1%)                   |
  |                                 8,446 (25.0%)    2,811 (24.7%)           2,
> 882 (25.7%)           2,753 (24.6%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Index of multiple deprivation                                              
>                                                0.29   |
  |    1 least deprived             23,652 (70.0%)   7,980 (70.2%)           7,
> 880 (70.3%)           7,792 (69.6%)                   |
  |    4                            6,702 (19.8%)    2,203 (19.4%)           2,
> 243 (20.0%)           2,256 (20.2%)                   |
  |    5 most deprived              3,415 (10.1%)    1,179 (10.4%)           1,
> 090 (9.7%)            1,146 (10.2%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | BMI                                                                        
>                                                0.40   |
  |    Underweight (<18.5)          76 (0.2%)        23 (0.2%)               31
>  (0.3%)               22 (0.2%)                       |
  |    Normal (18.5-24.9)           218 (0.6%)       90 (0.8%)               66
>  (0.6%)               62 (0.6%)                       |
  |    Overweight (25-29.9)         266 (0.8%)       104 (0.9%)              78
>  (0.7%)               84 (0.8%)                       |
  |    Obese I (30-34.9)            330 (1.0%)       112 (1.0%)              11
> 3 (1.0%)              105 (0.9%)                      |
  |    Obese II (35-39.9)           337 (1.0%)       110 (1.0%)              12
> 1 (1.1%)              106 (0.9%)                      |
  |    Obese III (40+)              568 (1.7%)       219 (1.9%)              17
> 9 (1.6%)              170 (1.5%)                      |
  |                                 31,974 (94.7%)   10,704 (94.2%)          10
> ,625 (94.8%)          10,645 (95.1%)                  |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Smoking status                                                             
>                                                0.98   |
  |    Never                        3,327 (9.9%)     1,102 (9.7%)            1,
> 128 (10.1%)           1,097 (9.8%)                    |
  |    Former                       1,638 (4.9%)     548 (4.8%)              55
> 3 (4.9%)              537 (4.8%)                      |
  |    Current                      10,111 (29.9%)   3,405 (30.0%)           3,
> 382 (30.2%)           3,324 (29.7%)                   |
  |                                 18,693 (55.4%)   6,307 (55.5%)           6,
> 150 (54.8%)           6,236 (55.7%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Hypertension                    6,818 (20.2%)    2,236 (19.7%)           2,
> 363 (21.1%)           2,219 (19.8%)            0.017  |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Diabetes                        6,783 (20.1%)    2,344 (20.6%)           2,
> 220 (19.8%)           2,219 (19.8%)            0.21   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | HbA1c                                                                      
>                                                0.23   |
  |    HbA1c <58mmol/mol            1,538 (4.6%)     625 (5.5%)              50
> 6 (4.5%)              407 (3.6%)                      |
  |    HbA1c >=58mmol/mol           264 (0.8%)       122 (1.1%)              80
>  (0.7%)               62 (0.6%)                       |
  |                                 31,967 (94.7%)   10,615 (93.4%)          10
> ,627 (94.8%)          10,725 (95.8%)                  |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Chronic cardiac disease         6,810 (20.2%)    2,244 (19.8%)           2,
> 292 (20.4%)           2,274 (20.3%)            0.39   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Stroke                          6,731 (19.9%)    2,294 (20.2%)           2,
> 200 (19.6%)           2,237 (20.0%)            0.56   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Cancer                          16,428 (48.6%)   5,557 (48.9%)           5,
> 423 (48.4%)           5,448 (48.7%)            0.71   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Chronic respiratory disease     6,766 (20.0%)    2,336 (20.6%)           2,
> 235 (19.9%)           2,195 (19.6%)            0.19   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Chronic liver disease           6,834 (20.2%)    2,343 (20.6%)           2,
> 281 (20.3%)           2,210 (19.7%)            0.25   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | Chronic kidney disease                                                     
>                                                0.15   |
  |    No CKD                       15,073 (44.6%)   4,995 (44.0%)           5,
> 012 (44.7%)           5,066 (45.3%)                   |
  |    CKD                          18,696 (55.4%)   6,367 (56.0%)           6,
> 201 (55.3%)           6,128 (54.7%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | eGFR                                                                       
>                                                0.12   |
  |    >=60/missing                 18,875 (55.9%)   6,255 (55.1%)           6,
> 328 (56.4%)           6,292 (56.2%)                   |
  |    30-59                        8,891 (26.3%)    3,014 (26.5%)           2,
> 912 (26.0%)           2,965 (26.5%)                   |
  |    <30                          6,003 (17.8%)    2,093 (18.4%)           1,
> 973 (17.6%)           1,937 (17.3%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------|
  | End-stage renal failure         6,769 (20.0%)    2,280 (20.1%)           2,
> 289 (20.4%)           2,200 (19.7%)            0.36   |
  +----------------------------------------------------------------------------
> ------------------------------------------------------+
Data are presented as mean (SD) for continuous measures, and n (%) for categori
> cal measures.
 

. restore

. 
. *Referral standards, by eia diagnosis
. preserve

. table1_mc, by(eia_diagnosis) total(before) onecol nospacelowpercent iqrmiddle
> (",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -------------------------+
  | factor                              N_T     N_1     N_2     N_3      m_T   
>    m_1      m_2      m_3 |
  |----------------------------------------------------------------------------
> -------------------------|
  | Time to GP referral                 987     342     318     327   34,401   
> 11,546   11,343   11,512 |
  | Time to GP referral                 987     342     318     327   34,401   
> 11,546   11,343   11,512 |
  |----------------------------------------------------------------------------
> -------------------------|
  | Time to rheumatology assessment   5,475   1,868   1,780   1,827   29,913   
> 10,020    9,881   10,012 |
  | Time to rheumatology assessment   5,475   1,868   1,780   1,827   29,913   
> 10,020    9,881   10,012 |
  +----------------------------------------------------------------------------
> -------------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -------------------------------+
  |                                   Total           RA              PsA      
>        AxSpA           p-value |
  |----------------------------------------------------------------------------
> -------------------------------|
  |                                   N=35,388        N=11,888        N=11,661 
>        N=11,839                |
  |----------------------------------------------------------------------------
> -------------------------------|
  | Time to GP referral                                                        
>                         0.31   |
  |    Referred within 3 days         10 (1.0%)       5 (1.5%)        3 (0.9%) 
>        2 (0.6%)                |
  |    Referred within 7 days         7 (0.7%)        4 (1.2%)        0 (0.0%) 
>        3 (0.9%)                |
  |    Referral delay >7 days         970 (98.3%)     333 (97.4%)     315 (99.1
> %)     322 (98.5%)             |
  | Time to GP referral                                                        
>                         0.54   |
  |    Referred within 3 days         10 (1.0%)       5 (1.5%)        3 (0.9%) 
>        2 (0.6%)                |
  |    Referral delay >3 days         977 (99.0%)     337 (98.5%)     315 (99.1
> %)     325 (99.4%)             |
  |----------------------------------------------------------------------------
> -------------------------------|
  | Time to rheumatology assessment                                            
>                         0.71   |
  |    Seen within 3 weeks            294 (5.4%)      97 (5.2%)       91 (5.1%)
>        106 (5.8%)              |
  |    Seen within 6 weeks            286 (5.2%)      98 (5.2%)       86 (4.8%)
>        102 (5.6%)              |
  |    Assessment delay >6 weeks      4,895 (89.4%)   1,673 (89.6%)   1,603 (90
> .1%)   1,619 (88.6%)           |
  | Time to rheumatology assessment                                            
>                         0.60   |
  |    Seen within 3 weeks            294 (5.4%)      97 (5.2%)       91 (5.1%)
>        106 (5.8%)              |
  |    Assessment delay >3 weeks      5,181 (94.6%)   1,771 (94.8%)   1,689 (94
> .9%)   1,721 (94.2%)           |
  +----------------------------------------------------------------------------
> -------------------------------+
Data are presented as n (%).
 

. restore

. 
. **With missing data
. preserve

. table1_mc, by(eia_diagnosis) total(before) missing onecol nospacelowpercent i
> qrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------+
  | factor                               N_T      N_1      N_2      N_3   m_T  
>  m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> -----------------|
  | Time to GP referral               35,388   11,888   11,661   11,839     0  
>    0     0     0 |
  | Time to GP referral               35,388   11,888   11,661   11,839     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Time to rheumatology assessment   35,388   11,888   11,661   11,839     0  
>    0     0     0 |
  | Time to rheumatology assessment   35,388   11,888   11,661   11,839     0  
>    0     0     0 |
  +----------------------------------------------------------------------------
> -----------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------+
  |                                   Total            RA               PsA    
>           AxSpA            p-value |
  |----------------------------------------------------------------------------
> -----------------------------------|
  |                                   N=35,388         N=11,888         N=11,66
> 1         N=11,839                 |
  |----------------------------------------------------------------------------
> -----------------------------------|
  | Time to GP referral                                                        
>                             0.31   |
  |    Referred within 3 days         10 (0.0%)        5 (0.0%)         3 (0.0%
> )         2 (0.0%)                 |
  |    Referred within 7 days         7 (0.0%)         4 (0.0%)         0 (0.0%
> )         3 (0.0%)                 |
  |    Referral delay >7 days         970 (2.7%)       333 (2.8%)       315 (2.
> 7%)       322 (2.7%)               |
  |    Missing                        34,401 (97.2%)   11,546 (97.1%)   11,343 
> (97.3%)   11,512 (97.2%)           |
  | Time to GP referral                                                        
>                             0.54   |
  |    Referred within 3 days         10 (0.0%)        5 (0.0%)         3 (0.0%
> )         2 (0.0%)                 |
  |    Referral delay >3 days         977 (2.8%)       337 (2.8%)       315 (2.
> 7%)       325 (2.7%)               |
  |    Missing                        34,401 (97.2%)   11,546 (97.1%)   11,343 
> (97.3%)   11,512 (97.2%)           |
  |----------------------------------------------------------------------------
> -----------------------------------|
  | Time to rheumatology assessment                                            
>                             0.71   |
  |    Seen within 3 weeks            294 (0.8%)       97 (0.8%)        91 (0.8
> %)        106 (0.9%)               |
  |    Seen within 6 weeks            286 (0.8%)       98 (0.8%)        86 (0.7
> %)        102 (0.9%)               |
  |    Assessment delay >6 weeks      4,895 (13.8%)    1,673 (14.1%)    1,603 (
> 13.7%)    1,619 (13.7%)            |
  |    Missing                        29,913 (84.5%)   10,020 (84.3%)   9,881 (
> 84.7%)    10,012 (84.6%)           |
  | Time to rheumatology assessment                                            
>                             0.60   |
  |    Seen within 3 weeks            294 (0.8%)       97 (0.8%)        91 (0.8
> %)        106 (0.9%)               |
  |    Assessment delay >3 weeks      5,181 (14.6%)    1,771 (14.9%)    1,689 (
> 14.5%)    1,721 (14.5%)            |
  |    Missing                        29,913 (84.5%)   10,020 (84.3%)   9,881 (
> 84.7%)    10,012 (84.6%)           |
  +----------------------------------------------------------------------------
> -----------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Referral standards, by year of diagnosis
. preserve

. table1_mc, by(diagnosis_year) total(before) onecol nospacelowpercent iqrmiddl
> e(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------------+
  | factor                              N_T   N_1     N_2     N_3      m_T     
>  m_1      m_2      m_3 |
  |----------------------------------------------------------------------------
> -----------------------|
  | Time to GP referral                 891    88     281     522   32,878   11
> ,274   10,932   10,672 |
  | Time to GP referral                 891    88     281     522   32,878   11
> ,274   10,932   10,672 |
  |----------------------------------------------------------------------------
> -----------------------|
  | Time to rheumatology assessment   5,088   835   1,764   2,489   28,681   10
> ,527    9,449    8,705 |
  | Time to rheumatology assessment   5,088   835   1,764   2,489   28,681   10
> ,527    9,449    8,705 |
  +----------------------------------------------------------------------------
> -----------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -------------------------------------------------------+
  |                                   Total           March 2019-March 2020   M
> arch 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -------------------------------------------------------|
  |                                   N=33,769        N=11,362                N
> =11,213                N=11,194                        |
  |----------------------------------------------------------------------------
> -------------------------------------------------------|
  | Time to GP referral                                                        
>                                                 0.19   |
  |    Referred within 3 days         9 (1.0%)        1 (1.1%)                2
>  (0.7%)                6 (1.1%)                        |
  |    Referred within 7 days         6 (0.7%)        2 (2.3%)                3
>  (1.1%)                1 (0.2%)                        |
  |    Referral delay >7 days         876 (98.3%)     85 (96.6%)              2
> 76 (98.2%)             515 (98.7%)                     |
  | Time to GP referral                                                        
>                                                 0.83   |
  |    Referred within 3 days         9 (1.0%)        1 (1.1%)                2
>  (0.7%)                6 (1.1%)                        |
  |    Referral delay >3 days         882 (99.0%)     87 (98.9%)              2
> 79 (99.3%)             516 (98.9%)                     |
  |----------------------------------------------------------------------------
> -------------------------------------------------------|
  | Time to rheumatology assessment                                            
>                                                <0.001  |
  |    Seen within 3 weeks            278 (5.5%)      75 (9.0%)               9
> 7 (5.5%)               106 (4.3%)                      |
  |    Seen within 6 weeks            270 (5.3%)      74 (8.9%)               9
> 0 (5.1%)               106 (4.3%)                      |
  |    Assessment delay >6 weeks      4,540 (89.2%)   686 (82.2%)             1
> ,577 (89.4%)           2,277 (91.5%)                   |
  | Time to rheumatology assessment                                            
>                                                <0.001  |
  |    Seen within 3 weeks            278 (5.5%)      75 (9.0%)               9
> 7 (5.5%)               106 (4.3%)                      |
  |    Assessment delay >3 weeks      4,810 (94.5%)   760 (91.0%)             1
> ,667 (94.5%)           2,383 (95.7%)                   |
  +----------------------------------------------------------------------------
> -------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. **With missing data
. preserve

. table1_mc, by(diagnosis_year) total(before) missing onecol nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------+
  | factor                               N_T      N_1      N_2      N_3   m_T  
>  m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> -----------------|
  | Time to GP referral               33,769   11,362   11,213   11,194     0  
>    0     0     0 |
  | Time to GP referral               33,769   11,362   11,213   11,194     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Time to rheumatology assessment   33,769   11,362   11,213   11,194     0  
>    0     0     0 |
  | Time to rheumatology assessment   33,769   11,362   11,213   11,194     0  
>    0     0     0 |
  +----------------------------------------------------------------------------
> -----------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> --------------------------------------------------------+
  |                                   Total            March 2019-March 2020   
> March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> --------------------------------------------------------|
  |                                   N=33,769         N=11,362                
> N=11,213                N=11,194                        |
  |----------------------------------------------------------------------------
> --------------------------------------------------------|
  | Time to GP referral                                                        
>                                                  0.19   |
  |    Referred within 3 days         9 (0.0%)         1 (0.0%)                
> 2 (0.0%)                6 (0.1%)                        |
  |    Referred within 7 days         6 (0.0%)         2 (0.0%)                
> 3 (0.0%)                1 (0.0%)                        |
  |    Referral delay >7 days         876 (2.6%)       85 (0.7%)               
> 276 (2.5%)              515 (4.6%)                      |
  |    Missing                        32,878 (97.4%)   11,274 (99.2%)          
> 10,932 (97.5%)          10,672 (95.3%)                  |
  | Time to GP referral                                                        
>                                                  0.83   |
  |    Referred within 3 days         9 (0.0%)         1 (0.0%)                
> 2 (0.0%)                6 (0.1%)                        |
  |    Referral delay >3 days         882 (2.6%)       87 (0.8%)               
> 279 (2.5%)              516 (4.6%)                      |
  |    Missing                        32,878 (97.4%)   11,274 (99.2%)          
> 10,932 (97.5%)          10,672 (95.3%)                  |
  |----------------------------------------------------------------------------
> --------------------------------------------------------|
  | Time to rheumatology assessment                                            
>                                                 <0.001  |
  |    Seen within 3 weeks            278 (0.8%)       75 (0.7%)               
> 97 (0.9%)               106 (0.9%)                      |
  |    Seen within 6 weeks            270 (0.8%)       74 (0.7%)               
> 90 (0.8%)               106 (0.9%)                      |
  |    Assessment delay >6 weeks      4,540 (13.4%)    686 (6.0%)              
> 1,577 (14.1%)           2,277 (20.3%)                   |
  |    Missing                        28,681 (84.9%)   10,527 (92.7%)          
> 9,449 (84.3%)           8,705 (77.8%)                   |
  | Time to rheumatology assessment                                            
>                                                 <0.001  |
  |    Seen within 3 weeks            278 (0.8%)       75 (0.7%)               
> 97 (0.9%)               106 (0.9%)                      |
  |    Assessment delay >3 weeks      4,810 (14.2%)    760 (6.7%)              
> 1,667 (14.9%)           2,383 (21.3%)                   |
  |    Missing                        28,681 (84.9%)   10,527 (92.7%)          
> 9,449 (84.3%)           8,705 (77.8%)                   |
  +----------------------------------------------------------------------------
> --------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. 
. *Referral standards, by region
. preserve

. table1_mc, by(nuts_region) total(before) onecol nospacelowpercent iqrmiddle("
> ,")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------+
  | factor                              N_T   N_1   N_2     N_3   N_4   N_5    
>  N_6   N_7   N_8      m_T     m_1     m_2     m_3     m_4     m_5     m_6    
>  m_7     m_8 |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------|
  | Time to GP referral                 987    91   121     189    93   101    
>  210    91    91   34,401   3,506   3,406   6,958   3,424   3,407   6,840   3
> ,508   3,352 |
  | Time to GP referral                 987    91   121     189    93   101    
>  210    91    91   34,401   3,506   3,406   6,958   3,424   3,407   6,840   3
> ,508   3,352 |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------|
  | Time to rheumatology assessment   5,475   549   540   1,095   539   549   1
> ,103   536   564   29,913   3,048   2,987   6,052   2,978   2,959   5,947   3
> ,063   2,879 |
  | Time to rheumatology assessment   5,475   549   540   1,095   539   549   1
> ,103   536   564   29,913   3,048   2,987   6,052   2,978   2,959   5,947   3
> ,063   2,879 |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------------------------------------+
  |                                   Total           East Midlands   East of E
> ngland   London          North East    North West    South East      West Mid
> lands   Yorkshire and the Humber   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------------------------------------|
  |                                   N=35,388        N=3,597         N=3,527  
>          N=7,147         N=3,517       N=3,508       N=7,050         N=3,599 
>         N=3,443                            |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------------------------------------|
  | Time to GP referral                                                        
>                                                                              
>                                     0.85   |
  |    Referred within 3 days         10 (1.0%)       1 (1.1%)        2 (1.7%) 
>          1 (0.5%)        1 (1.1%)      1 (1.0%)      3 (1.4%)        1 (1.1%)
>         0 (0.0%)                           |
  |    Referred within 7 days         7 (0.7%)        0 (0.0%)        0 (0.0%) 
>          2 (1.1%)        0 (0.0%)      0 (0.0%)      2 (1.0%)        1 (1.1%)
>         2 (2.2%)                           |
  |    Referral delay >7 days         970 (98.3%)     90 (98.9%)      119 (98.3
> %)       186 (98.4%)     92 (98.9%)    100 (99.0%)   205 (97.6%)     89 (97.8
> %)      89 (97.8%)                         |
  | Time to GP referral                                                        
>                                                                              
>                                     0.95   |
  |    Referred within 3 days         10 (1.0%)       1 (1.1%)        2 (1.7%) 
>          1 (0.5%)        1 (1.1%)      1 (1.0%)      3 (1.4%)        1 (1.1%)
>         0 (0.0%)                           |
  |    Referral delay >3 days         977 (99.0%)     90 (98.9%)      119 (98.3
> %)       188 (99.5%)     92 (98.9%)    100 (99.0%)   207 (98.6%)     90 (98.9
> %)      91 (100.0%)                        |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------------------------------------|
  | Time to rheumatology assessment                                            
>                                                                              
>                                     0.15   |
  |    Seen within 3 weeks            294 (5.4%)      29 (5.3%)       33 (6.1%)
>          50 (4.6%)       33 (6.1%)     22 (4.0%)     73 (6.6%)       27 (5.0%
> )       27 (4.8%)                          |
  |    Seen within 6 weeks            286 (5.2%)      21 (3.8%)       42 (7.8%)
>          57 (5.2%)       27 (5.0%)     30 (5.5%)     59 (5.3%)       24 (4.5%
> )       26 (4.6%)                          |
  |    Assessment delay >6 weeks      4,895 (89.4%)   499 (90.9%)     465 (86.1
> %)       988 (90.2%)     479 (88.9%)   497 (90.5%)   971 (88.0%)     485 (90.
> 5%)     511 (90.6%)                        |
  | Time to rheumatology assessment                                            
>                                                                              
>                                     0.29   |
  |    Seen within 3 weeks            294 (5.4%)      29 (5.3%)       33 (6.1%)
>          50 (4.6%)       33 (6.1%)     22 (4.0%)     73 (6.6%)       27 (5.0%
> )       27 (4.8%)                          |
  |    Assessment delay >3 weeks      5,181 (94.6%)   520 (94.7%)     507 (93.9
> %)       1,045 (95.4%)   506 (93.9%)   527 (96.0%)   1,030 (93.4%)   509 (95.
> 0%)     537 (95.2%)                        |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. **With missing data
. preserve

. table1_mc, by(nuts_region) total(before) onecol missing nospacelowpercent iqr
> middle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------+
  | factor                               N_T     N_1     N_2     N_3     N_4   
>   N_5     N_6     N_7     N_8   m_T   m_1   m_2   m_3   m_4   m_5   m_6   m_7
>    m_8 |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------|
  | Time to GP referral               35,388   3,597   3,527   7,147   3,517   
> 3,508   7,050   3,599   3,443     0     0     0     0     0     0     0     0
>      0 |
  | Time to GP referral               35,388   3,597   3,527   7,147   3,517   
> 3,508   7,050   3,599   3,443     0     0     0     0     0     0     0     0
>      0 |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------|
  | Time to rheumatology assessment   35,388   3,597   3,527   7,147   3,517   
> 3,508   7,050   3,599   3,443     0     0     0     0     0     0     0     0
>      0 |
  | Time to rheumatology assessment   35,388   3,597   3,527   7,147   3,517   
> 3,508   7,050   3,599   3,443     0     0     0     0     0     0     0     0
>      0 |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> -------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> ------------------------------------------------+
  |                                   Total            East Midlands   East of 
> England   London          North East      North West      South East      Wes
> t Midlands   Yorkshire and the Humber   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> ------------------------------------------------|
  |                                   N=35,388         N=3,597         N=3,527 
>           N=7,147         N=3,517         N=3,508         N=7,050         N=3
> ,599         N=3,443                            |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> ------------------------------------------------|
  | Time to GP referral                                                        
>                                                                              
>                                          0.85   |
  |    Referred within 3 days         10 (0.0%)        1 (0.0%)        2 (0.1%)
>           1 (0.0%)        1 (0.0%)        1 (0.0%)        3 (0.0%)        1 (
> 0.0%)        0 (0.0%)                           |
  |    Referred within 7 days         7 (0.0%)         0 (0.0%)        0 (0.0%)
>           2 (0.0%)        0 (0.0%)        0 (0.0%)        2 (0.0%)        1 (
> 0.0%)        2 (0.1%)                           |
  |    Referral delay >7 days         970 (2.7%)       90 (2.5%)       119 (3.4
> %)        186 (2.6%)      92 (2.6%)       100 (2.9%)      205 (2.9%)      89 
> (2.5%)       89 (2.6%)                          |
  |    Missing                        34,401 (97.2%)   3,506 (97.5%)   3,406 (9
> 6.6%)     6,958 (97.4%)   3,424 (97.4%)   3,407 (97.1%)   6,840 (97.0%)   3,5
> 08 (97.5%)   3,352 (97.4%)                      |
  | Time to GP referral                                                        
>                                                                              
>                                          0.95   |
  |    Referred within 3 days         10 (0.0%)        1 (0.0%)        2 (0.1%)
>           1 (0.0%)        1 (0.0%)        1 (0.0%)        3 (0.0%)        1 (
> 0.0%)        0 (0.0%)                           |
  |    Referral delay >3 days         977 (2.8%)       90 (2.5%)       119 (3.4
> %)        188 (2.6%)      92 (2.6%)       100 (2.9%)      207 (2.9%)      90 
> (2.5%)       91 (2.6%)                          |
  |    Missing                        34,401 (97.2%)   3,506 (97.5%)   3,406 (9
> 6.6%)     6,958 (97.4%)   3,424 (97.4%)   3,407 (97.1%)   6,840 (97.0%)   3,5
> 08 (97.5%)   3,352 (97.4%)                      |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> ------------------------------------------------|
  | Time to rheumatology assessment                                            
>                                                                              
>                                          0.15   |
  |    Seen within 3 weeks            294 (0.8%)       29 (0.8%)       33 (0.9%
> )         50 (0.7%)       33 (0.9%)       22 (0.6%)       73 (1.0%)       27 
> (0.8%)       27 (0.8%)                          |
  |    Seen within 6 weeks            286 (0.8%)       21 (0.6%)       42 (1.2%
> )         57 (0.8%)       27 (0.8%)       30 (0.9%)       59 (0.8%)       24 
> (0.7%)       26 (0.8%)                          |
  |    Assessment delay >6 weeks      4,895 (13.8%)    499 (13.9%)     465 (13.
> 2%)       988 (13.8%)     479 (13.6%)     497 (14.2%)     971 (13.8%)     485
>  (13.5%)     511 (14.8%)                        |
  |    Missing                        29,913 (84.5%)   3,048 (84.7%)   2,987 (8
> 4.7%)     6,052 (84.7%)   2,978 (84.7%)   2,959 (84.4%)   5,947 (84.4%)   3,0
> 63 (85.1%)   2,879 (83.6%)                      |
  | Time to rheumatology assessment                                            
>                                                                              
>                                          0.29   |
  |    Seen within 3 weeks            294 (0.8%)       29 (0.8%)       33 (0.9%
> )         50 (0.7%)       33 (0.9%)       22 (0.6%)       73 (1.0%)       27 
> (0.8%)       27 (0.8%)                          |
  |    Assessment delay >3 weeks      5,181 (14.6%)    520 (14.5%)     507 (14.
> 4%)       1,045 (14.6%)   506 (14.4%)     527 (15.0%)     1,030 (14.6%)   509
>  (14.1%)     537 (15.6%)                        |
  |    Missing                        29,913 (84.5%)   3,048 (84.7%)   2,987 (8
> 4.7%)     6,052 (84.7%)   2,978 (84.7%)   2,959 (84.4%)   5,947 (84.4%)   3,0
> 63 (85.1%)   2,879 (83.6%)                      |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------------------------
> ------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 months, for those with at least 6m registration
. preserve

. keep if has_6m_follow_up==1
(1,790 observations deleted)

. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent i
> qrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> --------------------+
  | factor                                  N_T      N_1      N_2      N_3   m_
> T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> --------------------|
  | csDMARD within 6 months              33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Methotrexate within 6 months         33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Sulfasalazine within 6 months        33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Hydroxychloroquine within 6 months   33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Leflunomide within 6 months          33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | bDMARD/tsDMARD within 6 months       33,598   11,295   11,071   11,232     
> 0     0     0     0 |
  +----------------------------------------------------------------------------
> --------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> --------------------------------------+
  |                                      Total            RA               PsA 
>              AxSpA            p-value |
  |----------------------------------------------------------------------------
> --------------------------------------|
  |                                      N=33,598         N=11,295         N=11
> ,071         N=11,232                 |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | csDMARD within 6 months                                                    
>                                0.40   |
  |    Yes                               1,422 (4.2%)     498 (4.4%)       461 
> (4.2%)       463 (4.1%)               |
  |    No                                8,176 (24.3%)    2,736 (24.2%)    2,64
> 4 (23.9%)    2,796 (24.9%)            |
  |    Missing                           24,000 (71.4%)   8,061 (71.4%)    7,96
> 6 (72.0%)    7,973 (71.0%)            |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | Methotrexate within 6 months                                               
>                                0.30   |
  |    Yes                               566 (1.7%)       200 (1.8%)       192 
> (1.7%)       174 (1.5%)               |
  |    No                                3,836 (11.4%)    1,283 (11.4%)    1,24
> 7 (11.3%)    1,306 (11.6%)            |
  |    Missing                           29,196 (86.9%)   9,812 (86.9%)    9,63
> 2 (87.0%)    9,752 (86.8%)            |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                0.58   |
  |    Yes                               303 (0.9%)       107 (0.9%)       91 (
> 0.8%)        105 (0.9%)               |
  |    No                                2,000 (6.0%)     697 (6.2%)       657 
> (5.9%)       646 (5.8%)               |
  |    Missing                           31,295 (93.1%)   10,491 (92.9%)   10,3
> 23 (93.2%)   10,481 (93.3%)           |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                0.52   |
  |    Yes                               284 (0.8%)       99 (0.9%)        94 (
> 0.8%)        91 (0.8%)                |
  |    No                                1,989 (5.9%)     656 (5.8%)       627 
> (5.7%)       706 (6.3%)               |
  |    Missing                           31,325 (93.2%)   10,540 (93.3%)   10,3
> 50 (93.5%)   10,435 (92.9%)           |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | Leflunomide within 6 months                                                
>                                0.72   |
  |    Yes                               303 (0.9%)       107 (0.9%)       93 (
> 0.8%)        103 (0.9%)               |
  |    No                                2,026 (6.0%)     670 (5.9%)       655 
> (5.9%)       701 (6.2%)               |
  |    Missing                           31,269 (93.1%)   10,518 (93.1%)   10,3
> 23 (93.2%)   10,428 (92.8%)           |
  |----------------------------------------------------------------------------
> --------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                0.36   |
  |    Yes                               4,391 (13.1%)    1,432 (12.7%)    1,47
> 7 (13.3%)    1,482 (13.2%)            |
  |    No                                15,571 (46.3%)   5,249 (46.5%)    5,10
> 9 (46.1%)    5,213 (46.4%)            |
  |    Missing                           13,636 (40.6%)   4,614 (40.8%)    4,48
> 5 (40.5%)    4,537 (40.4%)            |
  +----------------------------------------------------------------------------
> --------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 12 months, for those with at least 12m registrati
> on
. preserve

. keep if has_12m_follow_up==1
(3,516 observations deleted)

. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent i
> qrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------------+
  | factor                                   N_T      N_1      N_2      N_3   m
> _T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 12 months              31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 12 months         31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 12 months        31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 12 months   31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 12 months          31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 12 months       31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  +----------------------------------------------------------------------------
> ---------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -------------------------------------+
  |                                       Total            RA               PsA
>              AxSpA           p-value |
  |----------------------------------------------------------------------------
> -------------------------------------|
  |                                       N=31,872         N=10,761         N=1
> 0,467        N=10,644                |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | csDMARD within 12 months                                                   
>                               0.50   |
  |    Yes                                3,053 (9.6%)     1,028 (9.6%)     1,0
> 10 (9.6%)    1,015 (9.5%)            |
  |    No                                 6,027 (18.9%)    2,045 (19.0%)    1,9
> 24 (18.4%)   2,058 (19.3%)           |
  |    Missing                            22,792 (71.5%)   7,688 (71.4%)    7,5
> 33 (72.0%)   7,571 (71.1%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Methotrexate within 12 months                                              
>                               0.45   |
  |    Yes                                1,272 (4.0%)     439 (4.1%)       425
>  (4.1%)      408 (3.8%)              |
  |    No                                 2,882 (9.0%)     972 (9.0%)       928
>  (8.9%)      982 (9.2%)              |
  |    Missing                            27,718 (87.0%)   9,350 (86.9%)    9,1
> 14 (87.1%)   9,254 (86.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Sulfasalazine within 12 months                                             
>                               0.38   |
  |    Yes                                651 (2.0%)       235 (2.2%)       216
>  (2.1%)      200 (1.9%)              |
  |    No                                 1,525 (4.8%)     529 (4.9%)       481
>  (4.6%)      515 (4.8%)              |
  |    Missing                            29,696 (93.2%)   9,997 (92.9%)    9,7
> 70 (93.3%)   9,929 (93.3%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                               0.36   |
  |    Yes                                635 (2.0%)       199 (1.8%)       212
>  (2.0%)      224 (2.1%)              |
  |    No                                 1,520 (4.8%)     524 (4.9%)       478
>  (4.6%)      518 (4.9%)              |
  |    Missing                            29,717 (93.2%)   10,038 (93.3%)   9,7
> 77 (93.4%)   9,902 (93.0%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Leflunomide within 12 months                                               
>                               0.37   |
  |    Yes                                671 (2.1%)       218 (2.0%)       211
>  (2.0%)      242 (2.3%)              |
  |    No                                 1,546 (4.9%)     527 (4.9%)       509
>  (4.9%)      510 (4.8%)              |
  |    Missing                            29,655 (93.0%)   10,016 (93.1%)   9,7
> 47 (93.1%)   9,892 (92.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                               0.79   |
  |    Yes                                8,530 (26.8%)    2,850 (26.5%)    2,8
> 24 (27.0%)   2,856 (26.8%)           |
  |    No                                 10,373 (32.5%)   3,505 (32.6%)    3,3
> 90 (32.4%)   3,478 (32.7%)           |
  |    Missing                            12,969 (40.7%)   4,406 (40.9%)    4,2
> 53 (40.6%)   4,310 (40.5%)           |
  +----------------------------------------------------------------------------
> -------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m regi
> stration
. preserve

. keep if has_12m_follow_up==1
(3,516 observations deleted)

. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent i
> qrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------------+
  | factor                                   N_T      N_1      N_2      N_3   m
> _T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 6 months               31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 12 months              31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 6 months          31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 12 months         31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 6 months         31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 12 months        31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 6 months    31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 12 months   31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 6 months           31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 12 months          31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 6 months        31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 12 months       31,872   10,761   10,467   10,644    
>  0     0     0     0 |
  +----------------------------------------------------------------------------
> ---------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -------------------------------------+
  |                                       Total            RA               PsA
>              AxSpA           p-value |
  |----------------------------------------------------------------------------
> -------------------------------------|
  |                                       N=31,872         N=10,761         N=1
> 0,467        N=10,644                |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | csDMARD within 6 months                                                    
>                               0.60   |
  |    Yes                                1,353 (4.2%)     471 (4.4%)       439
>  (4.2%)      443 (4.2%)              |
  |    No                                 7,727 (24.2%)    2,602 (24.2%)    2,4
> 95 (23.8%)   2,630 (24.7%)           |
  |    Missing                            22,792 (71.5%)   7,688 (71.4%)    7,5
> 33 (72.0%)   7,571 (71.1%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | csDMARD within 12 months                                                   
>                               0.50   |
  |    Yes                                3,053 (9.6%)     1,028 (9.6%)     1,0
> 10 (9.6%)    1,015 (9.5%)            |
  |    No                                 6,027 (18.9%)    2,045 (19.0%)    1,9
> 24 (18.4%)   2,058 (19.3%)           |
  |    Missing                            22,792 (71.5%)   7,688 (71.4%)    7,5
> 33 (72.0%)   7,571 (71.1%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Methotrexate within 6 months                                               
>                               0.16   |
  |    Yes                                549 (1.7%)       196 (1.8%)       189
>  (1.8%)      164 (1.5%)              |
  |    No                                 3,605 (11.3%)    1,215 (11.3%)    1,1
> 64 (11.1%)   1,226 (11.5%)           |
  |    Missing                            27,718 (87.0%)   9,350 (86.9%)    9,1
> 14 (87.1%)   9,254 (86.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Methotrexate within 12 months                                              
>                               0.45   |
  |    Yes                                1,272 (4.0%)     439 (4.1%)       425
>  (4.1%)      408 (3.8%)              |
  |    No                                 2,882 (9.0%)     972 (9.0%)       928
>  (8.9%)      982 (9.2%)              |
  |    Missing                            27,718 (87.0%)   9,350 (86.9%)    9,1
> 14 (87.1%)   9,254 (86.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Sulfasalazine within 6 months                                              
>                               0.73   |
  |    Yes                                279 (0.9%)       99 (0.9%)        84 
> (0.8%)       96 (0.9%)               |
  |    No                                 1,897 (6.0%)     665 (6.2%)       613
>  (5.9%)      619 (5.8%)              |
  |    Missing                            29,696 (93.2%)   9,997 (92.9%)    9,7
> 70 (93.3%)   9,929 (93.3%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Sulfasalazine within 12 months                                             
>                               0.38   |
  |    Yes                                651 (2.0%)       235 (2.2%)       216
>  (2.1%)      200 (1.9%)              |
  |    No                                 1,525 (4.8%)     529 (4.9%)       481
>  (4.6%)      515 (4.8%)              |
  |    Missing                            29,696 (93.2%)   9,997 (92.9%)    9,7
> 70 (93.3%)   9,929 (93.3%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                               1.00   |
  |    Yes                                273 (0.9%)       91 (0.8%)        88 
> (0.8%)       94 (0.9%)               |
  |    No                                 1,882 (5.9%)     632 (5.9%)       602
>  (5.8%)      648 (6.1%)              |
  |    Missing                            29,717 (93.2%)   10,038 (93.3%)   9,7
> 77 (93.4%)   9,902 (93.0%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                               0.36   |
  |    Yes                                635 (2.0%)       199 (1.8%)       212
>  (2.0%)      224 (2.1%)              |
  |    No                                 1,520 (4.8%)     524 (4.9%)       478
>  (4.6%)      518 (4.9%)              |
  |    Missing                            29,717 (93.2%)   10,038 (93.3%)   9,7
> 77 (93.4%)   9,902 (93.0%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Leflunomide within 6 months                                                
>                               0.78   |
  |    Yes                                290 (0.9%)       100 (0.9%)       89 
> (0.9%)       101 (0.9%)              |
  |    No                                 1,927 (6.0%)     645 (6.0%)       631
>  (6.0%)      651 (6.1%)              |
  |    Missing                            29,655 (93.0%)   10,016 (93.1%)   9,7
> 47 (93.1%)   9,892 (92.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | Leflunomide within 12 months                                               
>                               0.37   |
  |    Yes                                671 (2.1%)       218 (2.0%)       211
>  (2.0%)      242 (2.3%)              |
  |    No                                 1,546 (4.9%)     527 (4.9%)       509
>  (4.9%)      510 (4.8%)              |
  |    Missing                            29,655 (93.0%)   10,016 (93.1%)   9,7
> 47 (93.1%)   9,892 (92.9%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                               0.84   |
  |    Yes                                4,200 (13.2%)    1,396 (13.0%)    1,3
> 89 (13.3%)   1,415 (13.3%)           |
  |    No                                 14,703 (46.1%)   4,959 (46.1%)    4,8
> 25 (46.1%)   4,919 (46.2%)           |
  |    Missing                            12,969 (40.7%)   4,406 (40.9%)    4,2
> 53 (40.6%)   4,310 (40.5%)           |
  |----------------------------------------------------------------------------
> -------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                               0.79   |
  |    Yes                                8,530 (26.8%)    2,850 (26.5%)    2,8
> 24 (27.0%)   2,856 (26.8%)           |
  |    No                                 10,373 (32.5%)   3,505 (32.6%)    3,3
> 90 (32.4%)   3,478 (32.7%)           |
  |    Missing                            12,969 (40.7%)   4,406 (40.9%)    4,2
> 53 (40.6%)   4,310 (40.5%)           |
  +----------------------------------------------------------------------------
> -------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 months, for those with at least 6m registration
> , for all patients by year of diagnosis
. preserve

. keep if has_6m_follow_up==1
(1,790 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> --------------------+
  | factor                                  N_T      N_1      N_2      N_3   m_
> T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> --------------------|
  | csDMARD within 6 months              32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Methotrexate within 6 months         32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Sulfasalazine within 6 months        32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Hydroxychloroquine within 6 months   32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | Leflunomide within 6 months          32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  |----------------------------------------------------------------------------
> --------------------|
  | bDMARD/tsDMARD within 6 months       32,062   10,806   10,653   10,603     
> 0     0     0     0 |
  +----------------------------------------------------------------------------
> --------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                      Total            March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                      N=32,062         N=10,806             
>    N=10,653                N=10,603                        |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                     0.91   |
  |    Yes                               1,356 (4.2%)     463 (4.3%)           
>    440 (4.1%)              453 (4.3%)                      |
  |    No                                7,826 (24.4%)    2,644 (24.5%)        
>    2,586 (24.3%)           2,596 (24.5%)                   |
  |    Missing                           22,880 (71.4%)   7,699 (71.2%)        
>    7,627 (71.6%)           7,554 (71.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                     0.32   |
  |    Yes                               538 (1.7%)       177 (1.6%)           
>    169 (1.6%)              192 (1.8%)                      |
  |    No                                3,676 (11.5%)    1,225 (11.3%)        
>    1,250 (11.7%)           1,201 (11.3%)                   |
  |    Missing                           27,848 (86.9%)   9,404 (87.0%)        
>    9,234 (86.7%)           9,210 (86.9%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                     0.42   |
  |    Yes                               292 (0.9%)       103 (1.0%)           
>    86 (0.8%)               103 (1.0%)                      |
  |    No                                1,911 (6.0%)     654 (6.1%)           
>    635 (6.0%)              622 (5.9%)                      |
  |    Missing                           29,859 (93.1%)   10,049 (93.0%)       
>    9,932 (93.2%)           9,878 (93.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                     0.66   |
  |    Yes                               269 (0.8%)       86 (0.8%)            
>    85 (0.8%)               98 (0.9%)                       |
  |    No                                1,914 (6.0%)     654 (6.1%)           
>    613 (5.8%)              647 (6.1%)                      |
  |    Missing                           29,879 (93.2%)   10,066 (93.2%)       
>    9,955 (93.4%)           9,858 (93.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                     0.016  |
  |    Yes                               286 (0.9%)       110 (1.0%)           
>    105 (1.0%)              71 (0.7%)                       |
  |    No                                1,935 (6.0%)     670 (6.2%)           
>    620 (5.8%)              645 (6.1%)                      |
  |    Missing                           29,841 (93.1%)   10,026 (92.8%)       
>    9,928 (93.2%)           9,887 (93.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                     0.51   |
  |    Yes                               4,180 (13.0%)    1,381 (12.8%)        
>    1,406 (13.2%)           1,393 (13.1%)                   |
  |    No                                14,860 (46.3%)   5,052 (46.8%)        
>    4,917 (46.2%)           4,891 (46.1%)                   |
  |    Missing                           13,022 (40.6%)   4,373 (40.5%)        
>    4,330 (40.6%)           4,319 (40.7%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 12 months, for those with at least 12m registrati
> on, by all patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1
(3,516 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------------+
  | factor                                   N_T      N_1      N_2      N_3   m
> _T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 12 months              30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 12 months         30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 12 months        30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 12 months   30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 12 months          30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 12 months       30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  +----------------------------------------------------------------------------
> ---------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> ------------------------------------------------------------+
  |                                       Total            March 2019-March 202
> 0   March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  |                                       N=30,412         N=10,228            
>     N=10,101                N=10,083                        |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                      0.89   |
  |    Yes                                2,925 (9.6%)     988 (9.7%)          
>     975 (9.7%)              962 (9.5%)                      |
  |    No                                 5,753 (18.9%)    1,946 (19.0%)       
>     1,891 (18.7%)           1,916 (19.0%)                   |
  |    Missing                            21,734 (71.5%)   7,294 (71.3%)       
>     7,235 (71.6%)           7,205 (71.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                      0.54   |
  |    Yes                                1,215 (4.0%)     392 (3.8%)          
>     407 (4.0%)              416 (4.1%)                      |
  |    No                                 2,762 (9.1%)     935 (9.1%)          
>     923 (9.1%)              904 (9.0%)                      |
  |    Missing                            26,435 (86.9%)   8,901 (87.0%)       
>     8,771 (86.8%)           8,763 (86.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                      0.66   |
  |    Yes                                627 (2.1%)       224 (2.2%)          
>     202 (2.0%)              201 (2.0%)                      |
  |    No                                 1,453 (4.8%)     489 (4.8%)          
>     485 (4.8%)              479 (4.8%)                      |
  |    Missing                            28,332 (93.2%)   9,515 (93.0%)       
>     9,414 (93.2%)           9,403 (93.3%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                      0.52   |
  |    Yes                                612 (2.0%)       201 (2.0%)          
>     208 (2.1%)              203 (2.0%)                      |
  |    No                                 1,453 (4.8%)     482 (4.7%)          
>     459 (4.5%)              512 (5.1%)                      |
  |    Missing                            28,347 (93.2%)   9,545 (93.3%)       
>     9,434 (93.4%)           9,368 (92.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                      0.58   |
  |    Yes                                638 (2.1%)       237 (2.3%)          
>     210 (2.1%)              191 (1.9%)                      |
  |    No                                 1,474 (4.8%)     515 (5.0%)          
>     491 (4.9%)              468 (4.6%)                      |
  |    Missing                            28,300 (93.1%)   9,476 (92.6%)       
>     9,400 (93.1%)           9,424 (93.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                      0.67   |
  |    Yes                                8,129 (26.7%)    2,775 (27.1%)       
>     2,687 (26.6%)           2,667 (26.5%)                   |
  |    No                                 9,902 (32.6%)    3,318 (32.4%)       
>     3,309 (32.8%)           3,275 (32.5%)                   |
  |    Missing                            12,381 (40.7%)   4,135 (40.4%)       
>     4,105 (40.6%)           4,141 (41.1%)                   |
  +----------------------------------------------------------------------------
> ------------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m regi
> stration, by all patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1
(3,516 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ---------------------+
  | factor                                   N_T      N_1      N_2      N_3   m
> _T   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 6 months               30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | csDMARD within 12 months              30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 6 months          30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Methotrexate within 12 months         30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 6 months         30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Sulfasalazine within 12 months        30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 6 months    30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Hydroxychloroquine within 12 months   30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 6 months           30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | Leflunomide within 12 months          30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 6 months        30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  |----------------------------------------------------------------------------
> ---------------------|
  | bDMARD/tsDMARD within 12 months       30,412   10,228   10,101   10,083    
>  0     0     0     0 |
  +----------------------------------------------------------------------------
> ---------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> ------------------------------------------------------------+
  |                                       Total            March 2019-March 202
> 0   March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  |                                       N=30,412         N=10,228            
>     N=10,101                N=10,083                        |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                      0.97   |
  |    Yes                                1,292 (4.2%)     439 (4.3%)          
>     428 (4.2%)              425 (4.2%)                      |
  |    No                                 7,386 (24.3%)    2,495 (24.4%)       
>     2,438 (24.1%)           2,453 (24.3%)                   |
  |    Missing                            21,734 (71.5%)   7,294 (71.3%)       
>     7,235 (71.6%)           7,205 (71.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                      0.89   |
  |    Yes                                2,925 (9.6%)     988 (9.7%)          
>     975 (9.7%)              962 (9.5%)                      |
  |    No                                 5,753 (18.9%)    1,946 (19.0%)       
>     1,891 (18.7%)           1,916 (19.0%)                   |
  |    Missing                            21,734 (71.5%)   7,294 (71.3%)       
>     7,235 (71.6%)           7,205 (71.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                      0.39   |
  |    Yes                                521 (1.7%)       171 (1.7%)          
>     164 (1.6%)              186 (1.8%)                      |
  |    No                                 3,456 (11.4%)    1,156 (11.3%)       
>     1,166 (11.5%)           1,134 (11.2%)                   |
  |    Missing                            26,435 (86.9%)   8,901 (87.0%)       
>     8,771 (86.8%)           8,763 (86.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                      0.54   |
  |    Yes                                1,215 (4.0%)     392 (3.8%)          
>     407 (4.0%)              416 (4.1%)                      |
  |    No                                 2,762 (9.1%)     935 (9.1%)          
>     923 (9.1%)              904 (9.0%)                      |
  |    Missing                            26,435 (86.9%)   8,901 (87.0%)       
>     8,771 (86.8%)           8,763 (86.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                      0.37   |
  |    Yes                                270 (0.9%)       98 (1.0%)           
>     79 (0.8%)               93 (0.9%)                       |
  |    No                                 1,810 (6.0%)     615 (6.0%)          
>     608 (6.0%)              587 (5.8%)                      |
  |    Missing                            28,332 (93.2%)   9,515 (93.0%)       
>     9,414 (93.2%)           9,403 (93.3%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                      0.66   |
  |    Yes                                627 (2.1%)       224 (2.2%)          
>     202 (2.0%)              201 (2.0%)                      |
  |    No                                 1,453 (4.8%)     489 (4.8%)          
>     485 (4.8%)              479 (4.8%)                      |
  |    Missing                            28,332 (93.2%)   9,515 (93.0%)       
>     9,414 (93.2%)           9,403 (93.3%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                      0.55   |
  |    Yes                                259 (0.9%)       78 (0.8%)           
>     88 (0.9%)               93 (0.9%)                       |
  |    No                                 1,806 (5.9%)     605 (5.9%)          
>     579 (5.7%)              622 (6.2%)                      |
  |    Missing                            28,347 (93.2%)   9,545 (93.3%)       
>     9,434 (93.4%)           9,368 (92.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                      0.52   |
  |    Yes                                612 (2.0%)       201 (2.0%)          
>     208 (2.1%)              203 (2.0%)                      |
  |    No                                 1,453 (4.8%)     482 (4.7%)          
>     459 (4.5%)              512 (5.1%)                      |
  |    Missing                            28,347 (93.2%)   9,545 (93.3%)       
>     9,434 (93.4%)           9,368 (92.9%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                      0.019  |
  |    Yes                                275 (0.9%)       105 (1.0%)          
>     104 (1.0%)              66 (0.7%)                       |
  |    No                                 1,837 (6.0%)     647 (6.3%)          
>     597 (5.9%)              593 (5.9%)                      |
  |    Missing                            28,300 (93.1%)   9,476 (92.6%)       
>     9,400 (93.1%)           9,424 (93.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                      0.58   |
  |    Yes                                638 (2.1%)       237 (2.3%)          
>     210 (2.1%)              191 (1.9%)                      |
  |    No                                 1,474 (4.8%)     515 (5.0%)          
>     491 (4.9%)              468 (4.6%)                      |
  |    Missing                            28,300 (93.1%)   9,476 (92.6%)       
>     9,400 (93.1%)           9,424 (93.5%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                      0.95   |
  |    Yes                                3,999 (13.1%)    1,348 (13.2%)       
>     1,325 (13.1%)           1,326 (13.2%)                   |
  |    No                                 14,032 (46.1%)   4,745 (46.4%)       
>     4,671 (46.2%)           4,616 (45.8%)                   |
  |    Missing                            12,381 (40.7%)   4,135 (40.4%)       
>     4,105 (40.6%)           4,141 (41.1%)                   |
  |----------------------------------------------------------------------------
> ------------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                      0.67   |
  |    Yes                                8,129 (26.7%)    2,775 (27.1%)       
>     2,687 (26.6%)           2,667 (26.5%)                   |
  |    No                                 9,902 (32.6%)    3,318 (32.4%)       
>     3,309 (32.8%)           3,275 (32.5%)                   |
  |    Missing                            12,381 (40.7%)   4,135 (40.4%)       
>     4,105 (40.6%)           4,141 (41.1%)                   |
  +----------------------------------------------------------------------------
> ------------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 months, for those with at least 6m registration
> , for RA patients by year of diagnosis
. preserve

. keep if has_6m_follow_up==1 & ra_code==1
(24,093 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------+
  | factor                                  N_T     N_1     N_2     N_3   m_T  
>  m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> -----------------|
  | csDMARD within 6 months              10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Methotrexate within 6 months         10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Sulfasalazine within 6 months        10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Hydroxychloroquine within 6 months   10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Leflunomide within 6 months          10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | bDMARD/tsDMARD within 6 months       10,741   3,635   3,521   3,585     0  
>    0     0     0 |
  +----------------------------------------------------------------------------
> -----------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                      Total            March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                      N=10,741         N=3,635              
>    N=3,521                 N=3,585                         |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                     0.42   |
  |    Yes                               479 (4.5%)       165 (4.5%)           
>    165 (4.7%)              149 (4.2%)                      |
  |    No                                2,614 (24.3%)    874 (24.0%)          
>    848 (24.1%)             892 (24.9%)                     |
  |    Missing                           7,648 (71.2%)    2,596 (71.4%)        
>    2,508 (71.2%)           2,544 (71.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                     0.76   |
  |    Yes                               192 (1.8%)       63 (1.7%)            
>    60 (1.7%)               69 (1.9%)                       |
  |    No                                1,228 (11.4%)    390 (10.7%)          
>    417 (11.8%)             421 (11.7%)                     |
  |    Missing                           9,321 (86.8%)    3,182 (87.5%)        
>    3,044 (86.5%)           3,095 (86.3%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                     0.91   |
  |    Yes                               105 (1.0%)       38 (1.0%)            
>    31 (0.9%)               36 (1.0%)                       |
  |    No                                670 (6.2%)       238 (6.5%)           
>    212 (6.0%)              220 (6.1%)                      |
  |    Missing                           9,966 (92.8%)    3,359 (92.4%)        
>    3,278 (93.1%)           3,329 (92.9%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                     0.95   |
  |    Yes                               92 (0.9%)        32 (0.9%)            
>    29 (0.8%)               31 (0.9%)                       |
  |    No                                628 (5.8%)       209 (5.7%)           
>    198 (5.6%)              221 (6.2%)                      |
  |    Missing                           10,021 (93.3%)   3,394 (93.4%)        
>    3,294 (93.6%)           3,333 (93.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                     0.007  |
  |    Yes                               102 (0.9%)       37 (1.0%)            
>    47 (1.3%)               18 (0.5%)                       |
  |    No                                637 (5.9%)       244 (6.7%)           
>    203 (5.8%)              190 (5.3%)                      |
  |    Missing                           10,002 (93.1%)   3,354 (92.3%)        
>    3,271 (92.9%)           3,377 (94.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                     0.36   |
  |    Yes                               1,355 (12.6%)    436 (12.0%)          
>    450 (12.8%)             469 (13.1%)                     |
  |    No                                4,991 (46.5%)    1,708 (47.0%)        
>    1,621 (46.0%)           1,662 (46.4%)                   |
  |    Missing                           4,395 (40.9%)    1,491 (41.0%)        
>    1,450 (41.2%)           1,454 (40.6%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 12 months, for those with at least 12m registrati
> on, by RA patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1 & ra_code==1
(24,627 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ------------------+
  | factor                                   N_T     N_1     N_2     N_3   m_T 
>   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 12 months              10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 12 months         10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 12 months        10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 12 months   10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 12 months          10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 12 months       10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  +----------------------------------------------------------------------------
> ------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                       Total           March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                       N=10,251        N=3,477              
>    N=3,363                 N=3,411                         |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                     0.098  |
  |    Yes                                992 (9.7%)      327 (9.4%)           
>    356 (10.6%)             309 (9.1%)                      |
  |    No                                 1,953 (19.1%)   658 (18.9%)          
>    628 (18.7%)             667 (19.6%)                     |
  |    Missing                            7,306 (71.3%)   2,492 (71.7%)        
>    2,379 (70.7%)           2,435 (71.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                     0.14   |
  |    Yes                                422 (4.1%)      126 (3.6%)           
>    159 (4.7%)              137 (4.0%)                      |
  |    No                                 930 (9.1%)      302 (8.7%)           
>    299 (8.9%)              329 (9.6%)                      |
  |    Missing                            8,899 (86.8%)   3,049 (87.7%)        
>    2,905 (86.4%)           2,945 (86.3%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                     0.84   |
  |    Yes                                228 (2.2%)      81 (2.3%)            
>    77 (2.3%)               70 (2.1%)                       |
  |    No                                 509 (5.0%)      178 (5.1%)           
>    164 (4.9%)              167 (4.9%)                      |
  |    Missing                            9,514 (92.8%)   3,218 (92.6%)        
>    3,122 (92.8%)           3,174 (93.1%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                     0.75   |
  |    Yes                                190 (1.9%)      65 (1.9%)            
>    63 (1.9%)               62 (1.8%)                       |
  |    No                                 500 (4.9%)      160 (4.6%)           
>    162 (4.8%)              178 (5.2%)                      |
  |    Missing                            9,561 (93.3%)   3,252 (93.5%)        
>    3,138 (93.3%)           3,171 (93.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                     0.80   |
  |    Yes                                210 (2.0%)      77 (2.2%)            
>    75 (2.2%)               58 (1.7%)                       |
  |    No                                 503 (4.9%)      196 (5.6%)           
>    168 (5.0%)              139 (4.1%)                      |
  |    Missing                            9,538 (93.0%)   3,204 (92.1%)        
>    3,120 (92.8%)           3,214 (94.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                     0.10   |
  |    Yes                                2,706 (26.4%)   884 (25.4%)          
>    917 (27.3%)             905 (26.5%)                     |
  |    No                                 3,343 (32.6%)   1,170 (33.6%)        
>    1,060 (31.5%)           1,113 (32.6%)                   |
  |    Missing                            4,202 (41.0%)   1,423 (40.9%)        
>    1,386 (41.2%)           1,393 (40.8%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m regi
> stration, by RA patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1 & ra_code==1
(24,627 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ------------------+
  | factor                                   N_T     N_1     N_2     N_3   m_T 
>   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 6 months               10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 12 months              10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 6 months          10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 12 months         10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 6 months         10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 12 months        10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 6 months    10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 12 months   10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 6 months           10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 12 months          10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 6 months        10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 12 months       10,251   3,477   3,363   3,411     0 
>     0     0     0 |
  +----------------------------------------------------------------------------
> ------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                       Total           March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                       N=10,251        N=3,477              
>    N=3,363                 N=3,411                         |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                     0.19   |
  |    Yes                                453 (4.4%)      153 (4.4%)           
>    165 (4.9%)              135 (4.0%)                      |
  |    No                                 2,492 (24.3%)   832 (23.9%)          
>    819 (24.4%)             841 (24.7%)                     |
  |    Missing                            7,306 (71.3%)   2,492 (71.7%)        
>    2,379 (70.7%)           2,435 (71.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                     0.098  |
  |    Yes                                992 (9.7%)      327 (9.4%)           
>    356 (10.6%)             309 (9.1%)                      |
  |    No                                 1,953 (19.1%)   658 (18.9%)          
>    628 (18.7%)             667 (19.6%)                     |
  |    Missing                            7,306 (71.3%)   2,492 (71.7%)        
>    2,379 (70.7%)           2,435 (71.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                     0.88   |
  |    Yes                                188 (1.8%)      62 (1.8%)            
>    61 (1.8%)               65 (1.9%)                       |
  |    No                                 1,164 (11.4%)   366 (10.5%)          
>    397 (11.8%)             401 (11.8%)                     |
  |    Missing                            8,899 (86.8%)   3,049 (87.7%)        
>    2,905 (86.4%)           2,945 (86.3%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                     0.14   |
  |    Yes                                422 (4.1%)      126 (3.6%)           
>    159 (4.7%)              137 (4.0%)                      |
  |    No                                 930 (9.1%)      302 (8.7%)           
>    299 (8.9%)              329 (9.6%)                      |
  |    Missing                            8,899 (86.8%)   3,049 (87.7%)        
>    2,905 (86.4%)           2,945 (86.3%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                     0.92   |
  |    Yes                                97 (0.9%)       35 (1.0%)            
>    30 (0.9%)               32 (0.9%)                       |
  |    No                                 640 (6.2%)      224 (6.4%)           
>    211 (6.3%)              205 (6.0%)                      |
  |    Missing                            9,514 (92.8%)   3,218 (92.6%)        
>    3,122 (92.8%)           3,174 (93.1%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                     0.84   |
  |    Yes                                228 (2.2%)      81 (2.3%)            
>    77 (2.3%)               70 (2.1%)                       |
  |    No                                 509 (5.0%)      178 (5.1%)           
>    164 (4.9%)              167 (4.9%)                      |
  |    Missing                            9,514 (92.8%)   3,218 (92.6%)        
>    3,122 (92.8%)           3,174 (93.1%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                     0.79   |
  |    Yes                                84 (0.8%)       27 (0.8%)            
>    30 (0.9%)               27 (0.8%)                       |
  |    No                                 606 (5.9%)      198 (5.7%)           
>    195 (5.8%)              213 (6.2%)                      |
  |    Missing                            9,561 (93.3%)   3,252 (93.5%)        
>    3,138 (93.3%)           3,171 (93.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                     0.75   |
  |    Yes                                190 (1.9%)      65 (1.9%)            
>    63 (1.9%)               62 (1.8%)                       |
  |    No                                 500 (4.9%)      160 (4.6%)           
>    162 (4.8%)              178 (5.2%)                      |
  |    Missing                            9,561 (93.3%)   3,252 (93.5%)        
>    3,138 (93.3%)           3,171 (93.0%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                     0.002  |
  |    Yes                                96 (0.9%)       33 (0.9%)            
>    47 (1.4%)               16 (0.5%)                       |
  |    No                                 617 (6.0%)      240 (6.9%)           
>    196 (5.8%)              181 (5.3%)                      |
  |    Missing                            9,538 (93.0%)   3,204 (92.1%)        
>    3,120 (92.8%)           3,214 (94.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                     0.80   |
  |    Yes                                210 (2.0%)      77 (2.2%)            
>    75 (2.2%)               58 (1.7%)                       |
  |    No                                 503 (4.9%)      196 (5.6%)           
>    168 (5.0%)              139 (4.1%)                      |
  |    Missing                            9,538 (93.0%)   3,204 (92.1%)        
>    3,120 (92.8%)           3,214 (94.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                     0.43   |
  |    Yes                                1,322 (12.9%)   433 (12.5%)          
>    430 (12.8%)             459 (13.5%)                     |
  |    No                                 4,727 (46.1%)   1,621 (46.6%)        
>    1,547 (46.0%)           1,559 (45.7%)                   |
  |    Missing                            4,202 (41.0%)   1,423 (40.9%)        
>    1,386 (41.2%)           1,393 (40.8%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                     0.10   |
  |    Yes                                2,706 (26.4%)   884 (25.4%)          
>    917 (27.3%)             905 (26.5%)                     |
  |    No                                 3,343 (32.6%)   1,170 (33.6%)        
>    1,060 (31.5%)           1,113 (32.6%)                   |
  |    Missing                            4,202 (41.0%)   1,423 (40.9%)        
>    1,386 (41.2%)           1,393 (40.8%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 months, for those with at least 6m registration
> , for PsA patients by year of diagnosis
. preserve

. keep if has_6m_follow_up==1 & psa_code==1
(24,317 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> -----------------+
  | factor                                  N_T     N_1     N_2     N_3   m_T  
>  m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> -----------------|
  | csDMARD within 6 months              10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Methotrexate within 6 months         10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Sulfasalazine within 6 months        10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Hydroxychloroquine within 6 months   10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | Leflunomide within 6 months          10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  |----------------------------------------------------------------------------
> -----------------|
  | bDMARD/tsDMARD within 6 months       10,607   3,567   3,581   3,459     0  
>    0     0     0 |
  +----------------------------------------------------------------------------
> -----------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> ----------------------------------------------------------+
  |                                      Total           March 2019-March 2020 
>   March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  |                                      N=10,607        N=3,567               
>   N=3,581                 N=3,459                         |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                    0.60   |
  |    Yes                               443 (4.2%)      143 (4.0%)            
>   149 (4.2%)              151 (4.4%)                      |
  |    No                                2,546 (24.0%)   879 (24.6%)           
>   849 (23.7%)             818 (23.6%)                     |
  |    Missing                           7,618 (71.8%)   2,545 (71.3%)         
>   2,583 (72.1%)           2,490 (72.0%)                   |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                    0.16   |
  |    Yes                               183 (1.7%)      56 (1.6%)             
>   55 (1.5%)               72 (2.1%)                       |
  |    No                                1,203 (11.3%)   409 (11.5%)           
>   407 (11.4%)             387 (11.2%)                     |
  |    Missing                           9,221 (86.9%)   3,102 (87.0%)         
>   3,119 (87.1%)           3,000 (86.7%)                   |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                    0.83   |
  |    Yes                               88 (0.8%)       32 (0.9%)             
>   29 (0.8%)               27 (0.8%)                       |
  |    No                                632 (6.0%)      210 (5.9%)            
>   214 (6.0%)              208 (6.0%)                      |
  |    Missing                           9,887 (93.2%)   3,325 (93.2%)         
>   3,338 (93.2%)           3,224 (93.2%)                   |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                    0.24   |
  |    Yes                               90 (0.8%)       26 (0.7%)             
>   36 (1.0%)               28 (0.8%)                       |
  |    No                                609 (5.7%)      220 (6.2%)            
>   193 (5.4%)              196 (5.7%)                      |
  |    Missing                           9,908 (93.4%)   3,321 (93.1%)         
>   3,352 (93.6%)           3,235 (93.5%)                   |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                    0.85   |
  |    Yes                               90 (0.8%)       32 (0.9%)             
>   32 (0.9%)               26 (0.8%)                       |
  |    No                                627 (5.9%)      215 (6.0%)            
>   212 (5.9%)              200 (5.8%)                      |
  |    Missing                           9,890 (93.2%)   3,320 (93.1%)         
>   3,337 (93.2%)           3,233 (93.5%)                   |
  |----------------------------------------------------------------------------
> ----------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                    0.97   |
  |    Yes                               1,414 (13.3%)   488 (13.7%)           
>   471 (13.2%)             455 (13.2%)                     |
  |    No                                4,900 (46.2%)   1,678 (47.0%)         
>   1,649 (46.0%)           1,573 (45.5%)                   |
  |    Missing                           4,293 (40.5%)   1,401 (39.3%)         
>   1,461 (40.8%)           1,431 (41.4%)                   |
  +----------------------------------------------------------------------------
> ----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 12 months, for those with at least 12m registrati
> on, by PsA patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1 & psa_code==1
(24,921 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ------------------+
  | factor                                   N_T     N_1     N_2     N_3   m_T 
>   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 12 months              10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 12 months         10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 12 months        10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 12 months   10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 12 months          10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 12 months       10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  +----------------------------------------------------------------------------
> ------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                       Total           March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                       N=10,024        N=3,366              
>    N=3,364                 N=3,294                         |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                     0.57   |
  |    Yes                                968 (9.7%)      338 (10.0%)          
>    307 (9.1%)              323 (9.8%)                      |
  |    No                                 1,851 (18.5%)   622 (18.5%)          
>    623 (18.5%)             606 (18.4%)                     |
  |    Missing                            7,205 (71.9%)   2,406 (71.5%)        
>    2,434 (72.4%)           2,365 (71.8%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                     0.037  |
  |    Yes                                408 (4.1%)      141 (4.2%)           
>    113 (3.4%)              154 (4.7%)                      |
  |    No                                 897 (8.9%)      299 (8.9%)           
>    309 (9.2%)              289 (8.8%)                      |
  |    Missing                            8,719 (87.0%)   2,926 (86.9%)        
>    2,942 (87.5%)           2,851 (86.6%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                     0.46   |
  |    Yes                                209 (2.1%)      78 (2.3%)            
>    68 (2.0%)               63 (1.9%)                       |
  |    No                                 461 (4.6%)      150 (4.5%)           
>    157 (4.7%)              154 (4.7%)                      |
  |    Missing                            9,354 (93.3%)   3,138 (93.2%)        
>    3,139 (93.3%)           3,077 (93.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                     0.72   |
  |    Yes                                205 (2.0%)      69 (2.0%)            
>    70 (2.1%)               66 (2.0%)                       |
  |    No                                 461 (4.6%)      161 (4.8%)           
>    143 (4.3%)              157 (4.8%)                      |
  |    Missing                            9,358 (93.4%)   3,136 (93.2%)        
>    3,151 (93.7%)           3,071 (93.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                     0.62   |
  |    Yes                                198 (2.0%)      72 (2.1%)            
>    71 (2.1%)               55 (1.7%)                       |
  |    No                                 489 (4.9%)      163 (4.8%)           
>    173 (5.1%)              153 (4.6%)                      |
  |    Missing                            9,337 (93.1%)   3,131 (93.0%)        
>    3,120 (92.7%)           3,086 (93.7%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                     0.009  |
  |    Yes                                2,705 (27.0%)   984 (29.2%)          
>    865 (25.7%)             856 (26.0%)                     |
  |    No                                 3,250 (32.4%)   1,063 (31.6%)        
>    1,125 (33.4%)           1,062 (32.2%)                   |
  |    Missing                            4,069 (40.6%)   1,319 (39.2%)        
>    1,374 (40.8%)           1,376 (41.8%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m regi
> stration, by PsA patients year of diagnosis
. preserve

. keep if has_12m_follow_up==1 & psa_code==1
(24,921 observations deleted)

. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent 
> iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear

  +----------------------------------------------------------------------------
> ------------------+
  | factor                                   N_T     N_1     N_2     N_3   m_T 
>   m_1   m_2   m_3 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 6 months               10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | csDMARD within 12 months              10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 6 months          10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Methotrexate within 12 months         10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 6 months         10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Sulfasalazine within 12 months        10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 6 months    10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Hydroxychloroquine within 12 months   10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 6 months           10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | Leflunomide within 12 months          10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 6 months        10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  |----------------------------------------------------------------------------
> ------------------|
  | bDMARD/tsDMARD within 12 months       10,024   3,366   3,364   3,294     0 
>     0     0     0 |
  +----------------------------------------------------------------------------
> ------------------+
   N_ ... #records used below,   m_ ... #records not used
 
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
  |                                       Total           March 2019-March 2020
>    March 2020-March 2021   March 2021-March 2022   p-value |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  |                                       N=10,024        N=3,366              
>    N=3,364                 N=3,294                         |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 6 months                                                    
>                                                     0.89   |
  |    Yes                                424 (4.2%)      141 (4.2%)           
>    144 (4.3%)              139 (4.2%)                      |
  |    No                                 2,395 (23.9%)   819 (24.3%)          
>    786 (23.4%)             790 (24.0%)                     |
  |    Missing                            7,205 (71.9%)   2,406 (71.5%)        
>    2,434 (72.4%)           2,365 (71.8%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | csDMARD within 12 months                                                   
>                                                     0.57   |
  |    Yes                                968 (9.7%)      338 (10.0%)          
>    307 (9.1%)              323 (9.8%)                      |
  |    No                                 1,851 (18.5%)   622 (18.5%)          
>    623 (18.5%)             606 (18.4%)                     |
  |    Missing                            7,205 (71.9%)   2,406 (71.5%)        
>    2,434 (72.4%)           2,365 (71.8%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 6 months                                               
>                                                     0.35   |
  |    Yes                                181 (1.8%)      57 (1.7%)            
>    54 (1.6%)               70 (2.1%)                       |
  |    No                                 1,124 (11.2%)   383 (11.4%)          
>    368 (10.9%)             373 (11.3%)                     |
  |    Missing                            8,719 (87.0%)   2,926 (86.9%)        
>    2,942 (87.5%)           2,851 (86.6%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Methotrexate within 12 months                                              
>                                                     0.037  |
  |    Yes                                408 (4.1%)      141 (4.2%)           
>    113 (3.4%)              154 (4.7%)                      |
  |    No                                 897 (8.9%)      299 (8.9%)           
>    309 (9.2%)              289 (8.8%)                      |
  |    Missing                            8,719 (87.0%)   2,926 (86.9%)        
>    2,942 (87.5%)           2,851 (86.6%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 6 months                                              
>                                                     0.43   |
  |    Yes                                82 (0.8%)       33 (1.0%)            
>    26 (0.8%)               23 (0.7%)                       |
  |    No                                 588 (5.9%)      195 (5.8%)           
>    199 (5.9%)              194 (5.9%)                      |
  |    Missing                            9,354 (93.3%)   3,138 (93.2%)        
>    3,139 (93.3%)           3,077 (93.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Sulfasalazine within 12 months                                             
>                                                     0.46   |
  |    Yes                                209 (2.1%)      78 (2.3%)            
>    68 (2.0%)               63 (1.9%)                       |
  |    No                                 461 (4.6%)      150 (4.5%)           
>    157 (4.7%)              154 (4.7%)                      |
  |    Missing                            9,354 (93.3%)   3,138 (93.2%)        
>    3,139 (93.3%)           3,077 (93.4%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 6 months                                         
>                                                     0.050  |
  |    Yes                                85 (0.8%)       24 (0.7%)            
>    37 (1.1%)               24 (0.7%)                       |
  |    No                                 581 (5.8%)      206 (6.1%)           
>    176 (5.2%)              199 (6.0%)                      |
  |    Missing                            9,358 (93.4%)   3,136 (93.2%)        
>    3,151 (93.7%)           3,071 (93.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Hydroxychloroquine within 12 months                                        
>                                                     0.72   |
  |    Yes                                205 (2.0%)      69 (2.0%)            
>    70 (2.1%)               66 (2.0%)                       |
  |    No                                 461 (4.6%)      161 (4.8%)           
>    143 (4.3%)              157 (4.8%)                      |
  |    Missing                            9,358 (93.4%)   3,136 (93.2%)        
>    3,151 (93.7%)           3,071 (93.2%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 6 months                                                
>                                                     0.87   |
  |    Yes                                86 (0.9%)       31 (0.9%)            
>    31 (0.9%)               24 (0.7%)                       |
  |    No                                 601 (6.0%)      204 (6.1%)           
>    213 (6.3%)              184 (5.6%)                      |
  |    Missing                            9,337 (93.1%)   3,131 (93.0%)        
>    3,120 (92.7%)           3,086 (93.7%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | Leflunomide within 12 months                                               
>                                                     0.62   |
  |    Yes                                198 (2.0%)      72 (2.1%)            
>    71 (2.1%)               55 (1.7%)                       |
  |    No                                 489 (4.9%)      163 (4.8%)           
>    173 (5.1%)              153 (4.6%)                      |
  |    Missing                            9,337 (93.1%)   3,131 (93.0%)        
>    3,120 (92.7%)           3,086 (93.7%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 6 months                                             
>                                                     0.36   |
  |    Yes                                1,327 (13.2%)   478 (14.2%)          
>    432 (12.8%)             417 (12.7%)                     |
  |    No                                 4,628 (46.2%)   1,569 (46.6%)        
>    1,558 (46.3%)           1,501 (45.6%)                   |
  |    Missing                            4,069 (40.6%)   1,319 (39.2%)        
>    1,374 (40.8%)           1,376 (41.8%)                   |
  |----------------------------------------------------------------------------
> -----------------------------------------------------------|
  | bDMARD/tsDMARD within 12 months                                            
>                                                     0.009  |
  |    Yes                                2,705 (27.0%)   984 (29.2%)          
>    865 (25.7%)             856 (26.0%)                     |
  |    No                                 3,250 (32.4%)   1,063 (31.6%)        
>    1,125 (33.4%)           1,062 (32.2%)                   |
  |    Missing                            4,069 (40.6%)   1,319 (39.2%)        
>    1,374 (40.8%)           1,376 (41.8%)                   |
  +----------------------------------------------------------------------------
> -----------------------------------------------------------+
Data are presented as n (%).
 

. restore

. 
. log close
      name:  <unnamed>
       log:  /workspace/logs/descriptive_tables.log
  log type:  text
 closed on:   6 Apr 2022, 14:51:59
-------------------------------------------------------------------------------
